Impact of switching from intravenous to oral linezolid therapy in Japanese patients: a retrospective cohort study

Akihiro Tanaka*, Akiko Yano, Shinichi Watanabe, Mamoru Tanaka and Hiroaki Araki

Abstract

Background: High oral bioavailability of antimicrobial agents can result in the replacement of intravenous (IV) therapy with oral therapy when a patient meets defined clinical criteria. However, few studies have evaluated the effects of switching antibiotic administration route in Japan, especially for linezolid. This study evaluated an IV-to-oral antibiotic switching program for linezolid treatment at a university hospital in Japan.

Methods: In a retrospective cohort study of 73 patients, we assessed the efficacy and safety of IV-to-oral linezolid therapy (n = 21 patients) compared with IV therapy alone (n = 52 patients).

Results: Duration of linezolid treatment, changes in C-reactive protein or platelet count from baseline, re-administration of anti-methicillin-resistant Staphylococcus aureus agent within 90 days of discharge, and mortality within 28 days of discharge were not significantly different between the two groups.

Conclusions: An IV-to-oral switching program could reduce the duration of IV linezolid therapy without worsening clinical outcomes in Japanese patients receiving linezolid therapy.

Keywords: Switching therapy, Linezolid, Cost

Background

Appropriate use of antimicrobial agents is important for clinical outcomes, patient safety, and minimizing drug resistance [1–3]. Stewardship programs promote judicious use of antimicrobial agents by selecting the appropriate drug, dose, duration, and route of administration [4].

The high oral bioavailability of antimicrobial agents such as fluoroquinolones, linezolid, fluconazole, and voriconazole justifies the conversion of intravenous (IV) therapy to oral therapy if a patient meets defined clinical criteria. IV-to-oral switching programs for antibiotics were implemented in several countries in the 1990s. This strategy can result in lower costs as well as reduced burden for nursing staff, prevalence of catheter-related infections, and duration of hospital stay [5, 6]. Few studies to date have evaluated the effects of switching administration routes for antibiotic therapy in Japan from IV to oral, especially for linezolid, which is why the present study was carried out. This study evaluated an IV-to-oral antibiotic switching program for linezolid treatment at a university hospital in Japan.

Methods

Design and study population

We conducted a retrospective cohort study of patients hospitalized at Ehime University Hospital (Ehime, Japan). The study was carried out in accordance with the guidelines for human studies adopted by the Ethics Committee of Ehime University Hospital (approval number: 1408002). Data were collected from records dating from 1 May 2009 to 30 April 2014.

We excluded patients who had received antibiotic therapy for <5 days, had neutropenic disease, or were aged <15 years. We divided patients into two groups, IV to oral therapy (IOT) and IV therapy alone (IVT). Criteria to define inappropriate IV administration of antibiotics were used in switching patients from IV to oral route. The criteria included: body temperature of 38 °C during the previous 24 h; decreased or normal
blood leucocyte count; absence of unexplained tachycardia; functional gastrointestinal tract (patient could eat or had a functional gastric feeding tube); and absence of vomiting, diarrhea, or severe sepsis [7]. In each case, pharmacists from the infection control team had recommended the switching from an IV route to an oral route. Assignment of patients to either group was determined by the attending physician, who also made the decision on whether to discontinue linezolid therapy.

**Outcome measures**
Several indicators were used to assess the efficacy and safety of switching from IV to oral linezolid therapy in comparison with IV therapy alone: decrease in C-reactive protein (CRP) level of ≥30 % from baseline; decrease in platelet count of ≥30 % from baseline; re-administration of an anti-methicillin-resistant *Staphylococcus aureus* (MRSA) agent <90 days after hospital discharge; and death <28 days after hospital discharge [8–10].

**Statistical analysis**
Statistical analysis was performed using add-in software for Mac Statistical Analysis v2.0 (Esumi, Tokyo, Japan). To compare differences in the distribution of baseline characteristics, we used the χ² test for binary data and Student’s *t*-test. The chi-squared test was used for discrete variables. Values of *p* < 0.05 were considered significant.

**Results**
Seventy-three patients were evaluated retrospectively. Baseline characteristics of the IOT group (21 patients) and IVT group (52 patients) are shown in Table 1. Age, sex, white blood cell count, CRP, and platelet count were similar between the groups.

Table 2 shows the clinical outcomes of the two groups. Duration of linezolid treatment, reduction in CRP level of ≥30 % from baseline, reduction in platelet count of ≥30 % from baseline, re-administration of an anti-MRSA agent <90 days after hospital discharge, and death <28 days after hospital discharge were not significantly different between the two groups.

Switching from IV to oral linezolid therapy was associated with a reduction in drug costs (¥2,540,820 [US$21,173]; average ¥9,964 [US$83]/day/person), as IV formulations (average ¥36,574 [US$305]/day/person) were more expensive (*p* < 0.001) than oral formulations (average ¥26,610 [US$222]/day/person).

**Discussion**
Reductions in CRP level and platelet count of ≥30 % from baseline were not significantly different between the IOT and IVT groups. Additionally, there was no significant difference in duration of linezolid treatment, re-administration of an anti-MRSA agent <90 days after hospital discharge, or death <28 days after hospital discharge between the two groups. These results suggest that switching from IV to oral linezolid therapy might be as effective and safe as maintaining patients on IV linezolid therapy alone.

A meta-analysis showed that earlier switching to antibiotic administration via the oral route was as effective as continuing IV therapy in patients with community-acquired pneumonia [11]. Similar results have been observed for intra-abdominal infections and spontaneous bacterial peritonitis [12, 13]. In Japan, earlier switching to antibiotic administration via the oral route has been shown to result in earlier clinical stability and reduced use of unnecessary antibiotics, without worsening clinical outcomes in patients hospitalized with mild and moderate community-acquired pneumonia [14]. However, reports on various MRSA infections acquired while receiving linezolid therapy are scarce. We therefore evaluated Japanese patients with various MRSA infections receiving linezolid therapy.

In the present study, the decision to implement IV therapy and to switch from IV to oral therapy was at the discretion of the attending physician. Incidence of switching from IV to oral linezolid therapy was low (21/73, 28.8 %), likely as a result of attending physicians’ attitudes towards switching administration route in Japan [14].

### Table 1 Statistical analysis of patient characteristics in the intravenous to oral therapy and intravenous therapy groups

|                          | Intravenous to oral therapy group | Intravenous therapy group | *p*-value |
|--------------------------|-----------------------------------|---------------------------|-----------|
| Age (years)              | 64 ± 19                           | 65 ± 16                   | 0.69      |
| Male (n [%])             | 19 (90.5)                         | 40 (76.9)                 | 0.18      |
| White blood cell count   | 8.8 ± 3.8                         | 10.6 ± 5.7                | 0.20      |
| CRP                      | 6.9 ± 4.8                         | 8.6 ± 6.7                 | 0.20      |
| Platelet count           | 25.5 ± 9.7                        | 23.2 ± 11.9               | 0.45      |

**Statistical analysis of patient characteristics** in the intravenous to oral therapy and intravenous therapy groups

*CRP* C-reactive protein; data are the mean ± standard deviation

*P*-values were calculated based on Students *t*-test or Welch’s *t*-test for continuous variables and chi-squared analysis for discrete variables.
**Table 2** Comparison of clinical outcomes between the two groups

|                          | Intravenous to oral therapy group (n = 21) | Intravenous therapy group (n = 52) | p-value |
|--------------------------|--------------------------------------------|-----------------------------------|---------|
| Duration of linezolid treatment (days) | 12 ± 5.8                                   | 14 ± 5.6                          | 0.22    |
| Reduction in level of CRP from baseline of ≥30 % (n [%]) | 16 (76.2)                                  | 38 (73.1)                         | 0.78    |
| Reduction in platelet count from baseline of ≥30 % (n [%]) | 7 (33.3)                                   | 20 (38.5)                         | 0.68    |
| Re-administration of an anti-MRSA agent <90 days after hospital discharge (n [%]) | 2 (9.5)                                    | 7 (13.5)                          | 0.64    |
| Death <28 days after hospital discharge (n [%]) | 3 (14.3)                                   | 10 (19.2)                         | 0.62    |
| Drug costs (/day/person) | US$222                                     | US$305                            | <0.001  |

MRSA, methicillin-resistant *Staphylococcus aureus*; data are the mean ± standard deviation.

The direct cost saving of switching from IV to oral linezolid therapy was $9,964 ($83)/day/person. Indirect costs of IV preparation and administration have been estimated to add 13 %–113 % to the costs of drugs [15]. The direct cost saving of switching from IV to oral linezolid therapy was significant. Therefore, we recommend switching from IV to oral linezolid therapy where applicable.

Our study had some limitations. First, it was not randomized in design, and data were collected retrospectively at a single institution. Second, a small sample size was included. Furthermore, a selection bias may have been present because it was the attending physician who decided whether to switch the administration route. Finally, we did not evaluate the length of hospital stay.

**Conclusions**

Switching from IV to oral linezolid therapy could reduce the duration of IV linezolid therapy without worsening clinical outcomes of Japanese patients. The direct cost saving of switching from IV to oral linezolid therapy was significant. However, our study was limited by its small sample size.

**Abbreviations**

CRP: C-reactive protein; IOT: IV to oral therapy; IV: Intravenous; IVT: IV therapy; MRSA: Anti-methicillin-resistant *Staphylococcus aureus*

**Acknowledgments**

Language editing was performed by Edanz.

**Funding**

Not applicable.

**Availability of data and materials**

Not applicable.

**Authors’ contributions**

AT contributed to data collection and analysis and wrote the manuscript. AY contributed to data collection and analysis. SW contributed to data analysis. MT contributed to study design and management. HA contributed to study design and revised the manuscript. All authors read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Consent for publication**

Not applicable.

**Ethics approval and consent to participate**

The study was carried out in accordance with the guidelines for human studies adopted by the Ethics Committee of Ehime University Hospital (approval number: 1408002). Participant consent was not applicable as patient data were evaluated retrospectively.

Received: 16 June 2016 Accepted: 19 October 2016
Published online: 28 October 2016

**References**

1. Gould IM. A review of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemother. 1999;43:459–65.
2. Burke JP. Infection control—a problem for patient safety. N Engl J Med. 2003;348:651–56.
3. Davey P, Brown E, Fenelon L, Finch R, Gould I, Holmes A, et al. Systematic review of antimicrobial drug prescribing in hospitals. Emerg Infect Dis. 2006;12:211–16.
4. Deliti Th, Owens RC, McGowan Jr JE, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159–77.
5. MacGregor RR, Graziani AL. Oral administration of antibiotics: a rational alternative to the parenteral route. Clin Infect Dis. 1997;24:657–67.
6. Seviç F, Prins JM, Koopmans RP, Langendijk PN, Bossuyt PM, Dankert J, et al. Early switch from intravenous to oral antibiotics guidelines and implementation in a large teaching hospital. J Antimicrob Chemother. 1999;43:601–6.
7. Vogel F. Intravenous/oral sequential therapy in patients hospitalised with community-acquired pneumonia. Drugs. 2002;52:309–17.
8. Neoh HM, Hori S, Komatsu M, Oguri T, Takeuchi F, Cui L, et al. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann Clin Microbiol Antimicrob. 2007;6:13.
9. Ichie T, Suzuki D, Yasui K, Takahashi H, Matsuda M, Hayashi H, et al. The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis. J Clin Pharm Ther. 2015;40:279–84.
10. Mertz D, Koller M, Haller P, Lampert ML, Plogge H, Hug B, et al. Outcomes of early switching from intravenous to oral antibiotics on medical wards. J Antimicrob Chemother. 2009;64:188–99.
11. Rhew DC, Tu GS, Orman J, Henning JM, Richards MS, Weingarten SR. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. Arch Intern Med. 2001;161:722–7.
12. Starak I, Karravas D, Asimakopoulos C, Kolaras P, Nikolaidis P, Harlaftis N, et al. Results of a prospective, randomized, double blind comparison of the efficacy and the safety of sequential ciprofloxacin (intravenous/oral) + metronidazole (intravenous/oral) with ceftriaxone (intravenous/oral) + metronidazole (intravenous/oral) for the treatment of intra-abdominal infections. Int J Antimicrob Agents. 2003;21:49–57.
13. Tuncer I, Topçu N, Durmus A, Türkdoğan MK. Oral ciprofloxacin versus intravenous cefotaxime and ceftriaxone in the treatment of spontaneous bacterial peritonitis. Hepatogastroenterology. 2003;50:1426–30.
14. Shindo Y, Sato S, Maruyama E, Ohashi T, Ogawa M, Imaizumi K, et al. Implication of clinical pathway care for community-acquired pneumonia in a community hospital: early switch from an intravenous beta-lactam plus a macrolide to an oral respiratory fluoroquinolone. Intern Med. 2008;47:1865–74.

15. van Zanten AR, Engelfriet PM, van Dillen K, van Veen M, Nuijten MJ, Polderman KH. Importance of nondrug costs of intravenous antibiotic therapy. Crit Care. 2003;7(R184–90).